[{"id":"a494ab91-02f5-4029-9cc0-0d8baf140054","acronym":"","url":"https://clinicaltrials.gov/study/NCT00456807","created_at":"2021-01-29T06:57:03.989Z","updated_at":"2024-07-02T16:37:27.005Z","phase":"Phase 3","brief_title":"Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged \u003e/= 26 Years","source_id_and_acronym":"NCT00456807","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD4 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cervarix (recombinant human papillomavirus bivalent vaccine)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 01/01/2008","study_completion_date":" 01/01/2008","last_update_posted":"2016-12-16"}]